MADISON, Wis., Nov 12 /PRNewswire/ -- Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer’s disease (AD) and schizophrenia. New product options have been developed for MCD-386, a clinical-stage drug candidate with “first-in-class” potential for improving memory and cognition in AD, improving cognition in schizophrenia, and for disease-modifying effects (or stopping disease progression) in AD. The new product options, all in preclinical research, include MCD-386 Forte (a high dose version), MCD-386 Transderm (potentially deliverable via a skin patch), and MCD-396 Forte/Transderm, combining the benefits of both technologies.
Trevor M Twose, CEO, will present these results in a corporate overview on Thursday November 12, 2009, at 12:05 p.m. at the 7th Annual MidAmerica Healthcare Venture Forum taking place on November 11-12, 2009, at the Monona Terrace conference center in Madison, WI. Mithridion is seeking major pharmaceutical company partners to develop its expanded product options. Dr. Twose will be available for one-on-one meetings.
MCD-386 Forte is a new high-dose product option, designed to maximize the disease-modifying potential of MCD-386.
Mithridion has proven the feasibility of these new product options in preclinical testing in laboratory models, not only for MCD-386, but also for one of the company’s new drug leads described below.
In its next-generation drug leads, currently in preclinical research, Mithridion has been successful in enhancing further the disease-modifying attributes for AD, and has been successful in adding new attributes potentially enhancing the profile of activity for treating not only cognitive impairment, but also psychotic symptoms in schizophrenia.
About Alzheimer’s Disease (AD)
Alzheimer’s disease is a progressive and fatal brain disease that destroys brain cells, causing problems with memory, thinking and behavior. Five million Americans suffer from AD today, and the number is expected to grow significantly. The market for AD drugs exceeds $4 billion, and may grow to greater than $10 billion with the development of drugs that are more effective.
CONTACT: Trevor M Twose, Chief Executive Officer of Mithridion, Inc.,
+1-608-332-8319, trevor@mithridion.com
Web site: http://www.mithridion.com/
